高眼压治疗研究20年随访:原发性开角型青光眼累积发病率与严重程度评估
该研究基于高眼压治疗研究(OHTS)20年随访数据,纳入1636例高眼压参与者,评估原发性开角型青光眼(POAG)的累积发病率和严重程度。经暴露时间调整后,20年POAG累积发病率为45.6%,观察组49.3%高于用药组41.9%,黑种人/非裔美国人达55.2%,视野缺损累积发病率为25.2%。
要点
- 高眼压患者20年POAG累积发病率为45.6%,观察组49.3%高于用药组41.9%。
- 黑种人/非裔美国人20年POAG累积发病率55.2%,高于其他种族42.7%。
- 20年视野缺损累积发病率为25.2%,仅约四分之一患者出现视野损害。
核心结论
- 高眼压研究参与者长期随访中仅约四分之一出现任一眼视野缺损。
- 该信息结合预测模型可帮助临床医生和患者对高眼压管理做出个性化决策。
研究设计与样本
- 研究为高眼压治疗研究(OHTS)的长期随访分析,参与者于1994年2月至2008年12月在22家诊所随访。
- 共1636例参与者随机入组,平均(SD)年龄55.4(9.6)岁,女性931例(56.9%),白种人1138例(69.6%),黑种人/非裔美国人407例(24.9%)。
- 第一阶段(1994年2月28日至2002年6月2日)随机接受局部降眼压药物或密切观察,第二阶段(2002年6月3日至2008年12月30日)两组均接受药物治疗。
- 第三阶段(2016年1月7日至2019年4月15日)进行眼科检查和视觉功能评估,数据分析于2019年7月至2020年12月进行。
主要发现
- 483例参与者(29.5%)在任一眼或双眼发生POAG(未调整发病率)。
- 经暴露时间调整后,所有参与者20年POAG累积发病率为45.6%(95%CI,42.3%-48.8%)。
- 观察组20年POAG累积发病率为49.3%(95%CI,44.5%-53.8%),用药组为41.9%(95%CI,37.2%-46.3%)。
- 黑种人/非裔美国人20年POAG累积发病率为55.2%(95%CI,47.9%-61.5%),其他种族为42.7%(95%CI,38.9%-46.3%)。
- 20年视野缺损累积发病率为25.2%(95%CI,22.5%-27.8%)。
关键数值与推荐
- 采用5因素基线模型,低、中、高风险三分位组POAG累积发病率分别为31.7%(95%CI,26.4%-36.6%)、47.6%(95%CI,41.6%-53.0%)和59.8%(95%CI,53.1%-65.5%)。
临床怎么用
- 临床医生可参考20年累积发病率和预测模型,结合风险分层对高眼压患者进行个性化管理决策。
- 黑种人/非裔美国人等高危人群的POAG累积发病率更高,需加强监测和干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Ocular hypertension is an important risk factor for the development of primary open-angle glaucoma (POAG). Data from long-term follow-up can be used to inform the management of patients with ocular hypertension. OBJECTIVE: To determine the cumulative incidence and severity of POAG after 20 years of follow-up among participants in the Ocular Hypertension Treatment Study. DESIGN, SETTING, AND PARTICIPANTS: Participants in the Ocular Hypertension Treatment Study were followed up from February 1994 to December 2008 in 22 clinics. Data were collected after 20 years of follow-up (from January 2016 to April 2019) or within 2 years of death. Analyses were performed from July 2019 to December 2020. INTERVENTIONS: From February 28, 1994, to June 2, 2002 (phase 1), participants were randomized to receive either topical ocular hypotensive medication (medication group) or close observation (observation group). From June 3, 2002, to December 30, 2008 (phase 2), both randomization groups received medication. Beginning in 2009, treatment was no longer determined by study protocol. From January 7, 2016, to April 15, 2019 (phase 3), participants received ophthalmic examinations and visual function assessments. MAIN OUTCOMES AND MEASURES: Twenty-year cumulative incidence and severity of POAG in 1 or both eyes after adjustment for exposure time. RESULTS: A total of 1636 individuals (mean [SD] age, 55.4 [9.6] years; 931 women [56.9%]; 1138 White participants [69.6%]; 407 Black/African American participants [24.9%]) were randomized in phase 1 of the clinical trial. Of those, 483 participants (29.5%) developed POAG in 1 or both eyes (unadjusted incidence). After adjusting for exposure time, the 20-year cumulative incidence of POAG in 1 or both eyes was 45.6% (95% CI, 42.3%-48.8%) among all participants, 49.3% (95% CI, 44.5%-53.8%) among participants in the observation group, and 41.9% (95% CI, 37.2%-46.3%) among participants in the medication group. The 20-year cumulative incidence of POAG was 55.2% (95% CI, 47.9%-61.5%) among Black/African American participants and 42.7% (95% CI, 38.9%-46.3%) among participants of other races. The 20-year cumulative incidence for visual field loss was 25.2% (95% CI, 22.5%-27.8%). Using a 5-factor baseline model, the cumulative incidence of POAG among participants in the low-, medium-, and high-risk tertiles was 31.7% (95% CI, 26.4%-36.6%), 47.6% (95% CI, 41.6%-53.0%), and 59.8% (95% CI, 53.1%-65.5%), respectively. CONCLUSIONS AND RELEVANCE: In this study, only one-fourth of participants in the Ocular Hypertension Treatment Study developed visual field loss in either eye over long-term follow-up. This information, together with a prediction model, may help clinicians and patients make informed personalized decisions about the management of ocular hypertension. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00000125.
引用
- Kass MA, Heuer DK, Higginbotham EJ, et al. Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up. JAMA Ophthalmol. 2021. PMID: 33856434. doi:10.1001/jamaophthalmol.2021.0341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。